3387-87-9 Usage
Uses
Used in Pharmaceutical Research and Development:
3,5-dichloro-D/L-Tyr is used as a precursor or intermediate in the synthesis of various compounds for pharmaceutical applications. Its unique structure and properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Disease Treatment and Therapy:
3,5-dichloro-D/L-Tyr is being investigated for its potential therapeutic properties in the treatment of various diseases and disorders. Its ability to modulate biological processes and pathways may contribute to the development of novel treatment options for patients.
Used in Chemical Synthesis:
3,5-dichloro-D/L-Tyr is utilized as a key component in the synthesis of a wide range of chemical compounds. Its unique structure and reactivity make it a versatile building block for the creation of new molecules with potential applications in various industries.
Used in Research Studies:
3,5-dichloro-D/L-Tyr is employed in research studies to explore its properties, mechanisms of action, and potential applications. 3,5-dichloro-D/L-Tyr serves as a valuable tool for scientists to gain insights into the underlying processes and pathways involved in various biological and chemical phenomena.
Check Digit Verification of cas no
The CAS Registry Mumber 3387-87-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,8 and 7 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 3387-87:
(6*3)+(5*3)+(4*8)+(3*7)+(2*8)+(1*7)=109
109 % 10 = 9
So 3387-87-9 is a valid CAS Registry Number.
3387-87-9Relevant academic research and scientific papers
Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents
Xu, Xi,Ge, Raoling,Li, Lei,Wang, Jubo,Lu, Xiaoyu,Xue, Siqi,Chen, Xijing,Li, Zhiyu,Bian, Jinlei
, p. 1325 - 1344 (2017/11/13)
Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.
